Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02).

Date publication

novembre 2022

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr KAMINSKY Marie-Christine

Tous les auteurs :
Racadot S, Thennevet I, Ouldbey Y, Kaminsky MC, Bosset M, Martin L, Tao Y, Sire C, de Raucourt D, Alfonsi M, Malaurie E, Tourani JM, Fournel P, Vauleon E, Modesto A, Rolland F, Metzger S, Pommier P, Chabaud S, Dussart S,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36434888

Résumé

We investigated the efficacy and safety of afatinib maintenance therapy in patients with head and neck squamous cell carcinoma (HNSCC) with macroscopically complete resection and adjuvant radiochemotherapy (RCT).

Mots clés

Cancer, Head and neck, Outcome, Post-operative chemoradiotherapy, Squamous cell carcinoma, Treatment-related toxicity

Référence

Eur J Cancer. 2022 11 9;178:114-127